Experts recommend assigning responsibility for neuroimplant care after Australian trials in advance
Experts recommend assigning responsibility for neuroimplant care after Australian trials in advance
On 3 September, The Conversation published an analysis of a new study. A multidisciplinary panel of 24 people developed 11 recommendations for Australian clinical trials of implantable neurodevices. The authors recommend discussing continued use of the device, available support, and compensation for harm related to trial participation before surgery.
A clinical trial ends according to schedule, but the device may remain in the participant's body. A neuroimplant is a device surgically placed in the brain or another part of the nervous system. It may require adjustments, software updates, replacement parts, specialist support, and sometimes surgery. After the trial, specific people and organizations need to remain responsible for providing this care.
In the article, specialists in bioethics, law, neurosurgery, engineering, clinical research, and patient advocacy proposed recommendations for Australia. The final vote included 14 panel members, and all 11 recommendations received at least 80% support.
During the consent process, participants should be told whether they will be able to continue using the device after the trial, which technical and clinical services will remain available, and under what conditions clinicians may recommend removal. The authors also recommend deciding who will maintain the device after the protocol ends while designing the study and conducting its ethical review. The participant's treating physician should be involved from the start of the study and receive its results and plans for subsequent care, while members of the research team may continue to handle adjustments and updates. A successor must be designated in case the original team becomes unavailable.
The plan should account for the distance to the research center, travel and accommodation costs, and the participant's financial circumstances. Insurance and compensation agreements should state explicitly which harms related to trial participation they will cover after the trial and for how long.
An international survey conducted in 2024 received responses from 66 researchers concerning 65 unique trials of implantable neurodevices. In 73% of cases, the research team was identified as one of the parties responsible for enabling participants to continue using the device after the study. The main barriers were funding, shortages of qualified specialists, and coordination among organizations.
The history of the Argus II retinal implant shows how this dependence on continued support works in practice. After Second Sight reduced support for the system in 2020, one user's external video processor fell and broke. In an IEEE Spectrum investigation, he said that another user and a physician helped him obtain a working replacement.
The Australian recommendations call for these arrangements to be completed before the first surgery. The plan should identify who will maintain the device, how participants can reach the appropriate specialist, and how responsibilities will be transferred.